Biogen [BIIB] vs Pfizer [PFE] Detailed Stock Comparison

Biogen Inc.

NASDAQ
Loading...

Pfizer Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Biogen Inc. wins in 10 metrics, Pfizer Inc. wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.

View Metrics Details

Vital Metrics Comparison

Metric Biogen Inc. Pfizer Inc. Better
P/E Ratio (TTM) 20.96 19.61 Pfizer Inc.
Price-to-Book Ratio 1.48 1.75 Biogen Inc.
Debt-to-Equity Ratio 36.47 77.96 Biogen Inc.
PEG Ratio -0.18 -0.04 Pfizer Inc.
EV/EBITDA 8.44 8.01 Pfizer Inc.
Profit Margin (TTM) 13.07% 12.42% Biogen Inc.
Operating Margin (TTM) 19.64% 23.95% Pfizer Inc.
EBITDA Margin (TTM) 19.64% 23.95% Pfizer Inc.
Return on Equity 7.39% 8.89% Pfizer Inc.
Return on Assets (TTM) 6.14% 5.68% Biogen Inc.
Free Cash Flow (TTM) $1.97B $9.08B Pfizer Inc.
Dividend Yield N/A 6.71% N/A
1-Year Return 51.01% 11.45% Biogen Inc.
Price-to-Sales Ratio (TTM) 2.73 2.42 Pfizer Inc.
Enterprise Value $30.41B $206.00B Pfizer Inc.
EV/Revenue Ratio 3.08 3.29 Biogen Inc.
Gross Profit Margin (TTM) 78.26% 69.97% Biogen Inc.
Revenue per Share (TTM) $68 $11 Biogen Inc.
Earnings per Share (Diluted) $8.79 $1.36 Biogen Inc.
Beta (Stock Volatility) 0.16 0.39 Biogen Inc.
Short % of Float 3.37% 2.33% Pfizer Inc.

Biogen Inc. vs Pfizer Inc. Stock Performance Analysis

Loading Price Chart...

BIIB
PFE

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Biogen Inc.3.78%-2.20%0.87%0.41%4.80%6.19%
Pfizer Inc.-0.82%-1.12%-2.81%-6.24%1.63%1.51%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Biogen Inc.51.01%-34.71%-31.50%-32.47%107.63%310.82%
Pfizer Inc.11.45%-31.75%-33.13%-20.45%32.42%14.07%

Performance & Financial Health Analysis: Biogen Inc. vs Pfizer Inc.

MetricBIIBPFE
Market Information
Market Cap i$27.06B$153.59B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i1,101,50330,662,931
90 Day Avg. Volume i1,198,65436,790,755
Last Close$195.96$25.34
52 Week Range$121.05 - $205.97$23.06 - $28.75
% from 52W High-4.86%-11.86%
All-Time High$480.18 (Mar 16, 2015)$61.71 (Dec 20, 2021)
% from All-Time High-59.19%-58.94%
Growth Metrics
Quarterly Revenue Growth-0.07%-0.01%
Quarterly Earnings Growth-0.07%-0.01%
Financial Health
Profit Margin (TTM) i0.13%0.12%
Operating Margin (TTM) i0.20%0.24%
Return on Equity (TTM) i0.07%0.09%
Debt to Equity (MRQ) i36.4777.96
Cash & Liquidity
Book Value per Share (MRQ)$124.37$15.21
Cash per Share (MRQ)$26.00$2.39
Operating Cash Flow (TTM) i$2.20B$11.70B
Levered Free Cash Flow (TTM) i$1.98B$13.43B
Dividends
Last 12-Month Dividend Yield iN/A6.71%
Last 12-Month Dividend iN/A$1.72

Valuation & Enterprise Metrics Analysis: Biogen Inc. vs Pfizer Inc.

MetricBIIB (Apr 26, 2026)PFE (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i20.9619.61
Forward P/E i11.519.48
PEG Ratio i-0.18-0.04
Price to Sales (TTM) i2.732.42
Price to Book (MRQ) i1.481.75
Market Capitalization
Market Capitalization i$27.06B$153.59B
Enterprise Value i$30.41B$206.00B
Enterprise Value Metrics
Enterprise to Revenue i3.083.29
Enterprise to EBITDA i8.448.01
Risk & Other Metrics
Beta i0.160.39
Book Value per Share (MRQ) i$124.37$15.21

Financial Statements Comparison: Biogen Inc. vs Pfizer Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBIIB (2025)PFE (2025)
Revenue/Sales i9.89B62.58B
Cost of Goods Sold i2.40B16.07B
COGS % of Revenue i24.3%25.7%
Gross Profit i7.49B46.51B
Gross Margin i75.7%74.3%
Research & Development i1.78B10.44B
Operating Income (EBIT) i2.47B17.41B
Operating Margin i25.0%27.8%
EBITDA i3.40B25.75B
EBITDA Margin i34.4%41.1%
Pre-Tax Income i1.56B7.52B
Pre-Tax Income % of Revenue i15.7%12.0%
Income Tax i263.60M-266.00M
Income Tax % of Revenue i2.7%-0.4%
Net Income (Profit) i1.29B7.81B
Profit Margin i13.1%12.5%

Balance Sheet & Liquidity Metrics

MetricBIIB (2025)PFE (2025)
Cash & Equivalents i3.01B1.14B
Total Current Assets i8.97B42.90B
Total Current Assets % of Revenue i90.7%68.6%
Total Current Liabilities i3.35B36.98B
Total Current Liabilities % of Revenue i33.9%59.1%
Long-Term Debt i6.58B60.81B
Long-Term Debt % of Revenue i66.5%97.2%
Total Shareholders Equity i18.26B86.78B
Retained Earnings i20.55B114.61B
Retained Earnings % of Revenue i207.8%183.1%
Property, Plant & Equipment i265.40M0

Cash Flow Statement Comparison

MetricBIIB (2025)PFE (2025)
Operating Cash Flow i1.95B6.43B
Operating Cash Flow % of Revenue i19.8%10.3%
Capital Expenditures i-153.80M-2.63B
Free Cash Flow i1.97B9.08B
FCF Margin i19.9%14.5%
Debt Repayment i-1.75B-9.75B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricBIIBPFE
Shares Short i3.83M132.47M
Short Ratio i3.963.17
Short % of Float i3.37%2.33%
Shares Outstanding i146.80M5.69B
Float Shares i146.28M5.68B
% Held by Insiders i0.17%0.10%
% Held by Institutions i98.82%68.38%
% Held by Public i1.01%31.52%

Dividend Analysis & Yield Comparison: Biogen Inc. vs Pfizer Inc.

MetricBIIBPFE
Last 12-Month Dividend iN/A$1.72
Last 12-Month Dividend Yield iN/A6.71%
3-Year Avg Annual Dividend iN/A$1.69
3-Year Avg Dividend Yield iN/A1.54%
3-Year Total Dividends iN/A$5.06
Ex-Dividend DateN/AJan 23, 2026